Clinically Meaningful Improvements With Ozanimod in UC Trial
The True North study included patients with moderate to severe ulcerative colitis who had an inadequate response to prior treatment.
Colorectal Disorders
Prevalence of Adverse Pregnancy Outcomes Assessed With Biologics for IBD
The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.
Results Mixed for Etrolizumab in Ulcerative Colitis
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody designed to selectively inhibit α4β7 and αEβ7 integrins.
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
CRC Risk Down With ACEi, Angiotensin Receptor Blocker Use
Five percent reduction in adjusted hazard ratio risk with each single year increase in drug use.
Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma
Guideline Issued on the Use of Probiotics for Managing GI Disorders
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.
Clinical Remission Observed With Ozanimod in Ulcerative Colitis Trial
Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis.
